Exhibit 99.1

CORPORATE PRESENTATION Frank Bedu-Addo Ph.D. President & CEO SEPTEMBER 2020

2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation (“PDSB”), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activities and timelines and market opportunities. All statements other than statements of historical facts included in this presentation are forward-looking statements. The words “anticipates,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “intends,” “likely,” “will,” “should,” “to be,” and any similar expressions or other words of similar meaning are intended to identify those assertions as forward-looking statements. These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those anticipated.Factors that may cause actual results to differ materially from such forward-looking statements include those identified under the caption “Risk Factors” in the documents filed with the Securities and Exchange Commission from time to time, including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Except to the extent required by applicable law or regulation, PDSB undertakes no obligation to update the forward-looking statements included in this presentation to reflect subsequent events or circumstances.

PDS Biotechnology leadership team has demonstrated success in the development and commercialization of leading pharmaceutical products 3 Senior executive experience with management of strategy and execution at both large pharma and biotechsNotable drug development:Abelcet® (Liposome Company/ Elan)PEG-Intron® (Schering-Plough/ Merck) Senior executive experience with over 20 years of experience in pharma and drug developmentIn-depth experience with M&A transactions, capital markets, and investor relations >30 years of translational clinical research experienceFormer Director of Clinical Research at National Cancer Institute Center for Cancer Research (Cancer Vaccine Branch) Co-founder>35 years of drug development experience In-depth experience with biotech drug discovery, product development and manufacturing Frank Bedu-Addo, PhDChief Executive Officer Gregory Conn, PhDChief Scientific Officer Lauren V. Wood, MDChief Medical Officer Michael KingChief Financial Officer (Interim)

PDS Biotech is well-poised to transform vaccines and cancer treatment by delivering promising immunotherapies 4 Clinical studies in areas of high unmet medical need supported by leaders in the field 4 Diversified pipeline focused on oncology and infectious disease 3 Demonstrated potential for strong clinical efficacy and durability of response with minimal toxicity 2 Powerful immunotherapy platform that activates therapeutic and preventive immunological pathways 1

PDS Biotech is a clinical stage biotechnology company developing a pipeline of immunotherapies based on the proprietary Versamune® platform 5 Versatile and potent T-cell-activating platformClinically supported induction of active antigen-specific killer and helper T-cells in vivoPromising clinical efficacy demonstrated in early trials of PDS0101 monotherapy with favorable safety profile and no dose limiting toxicities Publicly listed on NASDAQ: PDSB~15 employees with headquarters in Florham Park and Princeton, NJ22.3M shares outstanding with approximately $34.0M in cash* Pipeline Versamune® Platform Corporate Overview * September 11, 2020

6 Reference: Data on file. PDS Biotech’s pipeline combines the Versamune® platform with proprietary antigens across immuno-oncology and infectious disease

Versamune® Platform

v Versamune® is based on proprietary, positively charged and immune activating lipids that form spherical nanoparticles in aqueous media The nanoparticles are sized to mimic viruses, which promotes excellent uptake by dendritic cells of the immune systemActivates the important Type I interferon immunological signaling pathwayVersamune® promotes the activation and maturation of dendritic cells, which then migrate to the lymph nodes Versamune®: proprietary T-cell activating platform Engineered to induce robust, targeted anti-tumor responses in vivo 8 Water-insolubleFatty acids/hydrocarbon chains Water-soluble and positively charged head-group coats the particle surface R-enantiomer of 1,2-dioleoyl-trimethyl-ammonium-propane (R-DOTAP)

Inability to perform the necessary steps to induce a strong therapeutic killer T-cell response in-vivo Versamune® design and novel immunological mechanisms of action promote a powerful disease-specific killer T-cell response Versamune® has demonstrated potential to overcome well-established challenges of immunotherapy in oncology and infectious disease 9 Challenges of Immunotherapy How Versamune® May Overcome the Challenges Mechanistic limitations have resulted in lack of therapeutic benefit in human studies Mechanism of action associated with regression of disease in human studies (PDS0101 monotherapy) Potential for systemic toxicities Mechanism of action results in a lack of clinically relevant toxicities, even at the highest dose, in human studies Reference: Gandhapudi SK, Ward M, Bush JPC, Bedu-Addo F, Conn G, Woodward JG. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536.

Greater quantity and quality of Versamune®-induced killer T-cells may result in unique ability to eradicate HPV-positive tumors after a single dose 10 Produces > 10-fold number of highly potent (polyfunctional) killer T-cells vs. other T-cell technologies Single treatment dose Results typical of current topclinical-stage HPV cancer vaccines Tumor rechallenge at Day 60; complete and sustained cure of cancer *Adjuvant = cytokine GMCSFReferences: J. Immunology, 2019 (202), 1215; Studies in TC-1 tumor model with other immunotherapies reported in: Vaccine 2009, January 14, 27 (3): 431; Science Translational Medicine 2016, 13 April, Vol 8 Issue 334; Vaccine 2009, September 25, 27 (42): 5906.

11 Combination of Versamune® and a proprietary antigenEngineered for simplicity and ease of administration Vials of HPV16 mix (L)and Versamune® (R) Versamune® formulationis mixed before injection* Delivered viasubcutaneous injection *Electron microscopy picture

Oncology

Checkpoint inhibitors have shown confirmed clinical efficacy and have demonstrated clinical benefit in late stage cancerCheckpoint inhibitors block a key immunological defense mechanism for cancer cells, and are reported to work primarily in patients whose immune systems are already generating tumor-attacking CD8+ killer T-cells pre-treatmentUsing various tumor-specific proteins (antigens), Versamune® has demonstrated the ability to generate large and superior numbers of CD8+ killer T-cells relative to other immunotherapies, that effectively recognize and kill antigen-expressing cancer cells in pre-clinical and human clinical studies Clinical strategy in advanced cancer:Focus on efficiency and risk mitigation to proof of concept 13 Versamune®-based immunotherapies are being developed as combination therapies to exploit the demonstrated synergies between Versamune® and other anti-cancer agents PDS Biotech is developing a new generation of advanced cancer treatments combining Versamune®-based immunotherapies with checkpoint inhibitors and other standard of care therapies

Versamune®-based immunotherapy + checkpoint inhibitors: Strong synergy leads to enhanced anti-tumor efficacy 14 Preclinical studies: Checkpoint inhibitor ineffective in treating B16 melanoma, a notoriously difficult modelPDS0104 promotes infiltration of active killer T-cells into tumors + Checkpoint inhibitor blocks tumor immune suppressive mechanism = Enhanced anti-tumor efficacy References: Gandhapudi SK et al. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536. Vasievich EA et al. 2012. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model. Mol Pharmaceutics. 9(2): 261-268. CD4+ helper T-cell CD8+ killer T-cell

15 PDS0101 designed to treat cancers caused by human papillomavirus (HPV) Approximately 43,000 patients are diagnosed with cancers where HPV is often found each year in US; approximately 35,000 cases are caused directly by HPV References: Markowitz et al. 2016. Centers for Disease Control and Prevention. 2018. Oropharyngeal (head & neck) cancers >18,000 cases annuallyMost common HPV-cancer in men,90% of cases are HPV16-specificIncidence increasingCervical cancer~12,000 cases annuallyMost common HPV-cancer in women,50-60% of cases are HPV16-specificIncidence steadyInitial market research suggests market penetration of ~20% is reasonable for PDS0101 PDS0101 combines the utility of Versamune® with a proprietary mix of HPV16 antigens, the most virulent high-risk HPV type, and by far the most prevalent in patients with HPV-associated cancer Females (24,391) Males (18,280)

16 PDS0101 Phase 1 clinical trial: Unique in vivo demonstration of high levels of HPV-specific killer T-cells in circulating blood 14x 24x Total Activated T-Cells 26x Order of magnitude increase over baseline Versamune® Dose Reference: Data on file. INF-γ Elispot Granzyme-b Elispot Clinical Study Results in Patients with CINImmunogenicity at Day 14Defined dose for Phase 2 studies (3mg)No dose-limiting toxicities Clinical study results successfully demonstrate translation of Versamune®’s multi-functional mechanism of action between pre-clinical models and humans

17 Follow-up of patients in PDS0101 Phase 1 study demonstrated promising clinical responses at all three tested doses A post-hoc, retrospective analysis, demonstrated complete lesion regression in at least 60% of evaluable patients (6/10) as early as 1-3 months after treatmentNo lesion recurrence occurred within the 2-year evaluation periodSpontaneous regression of CIN1 occurs in about 44% of patients over a 2-year duration* These results were remarkably positive as most patients were infected with multiple high-risk HPV typesTwo patients who had regression by cytology were not considered clinical responders:The first regressed to atypical cells of undetermined significance at the first post-treatment evaluation (3 months) but HPV detectedThe second had complete regression by cytology at the first post-treatment evaluation (3 months) but had residual CIN by colposcopy Reference: Stefani C. et al, 2014, European Review for Medical and Pharmacological Sciences, 18: 728-733

18 Investigator-Led Phase 2 studies of PDS0101 in combination therapy will evaluate efficacy and safety in treatment of advanced HPV cancers Funded By Phase 2 Open Label Study (Safety and Efficacy) Important Considerations Initiation Advanced HPV-associated malignancies – all typesTriple combination with EMD Serono’s M7824 and NHS-IL1228 subjectsClinical Trial Identifier: NCT04287868 NCI selection and confirmation of synergies with PDS0101All three agents have demonstrated efficacy as monotherapies in early trials Initiated in June 2020 Advanced, localized cervical cancer (Stage IIb-IVa)Combination with chemo-radiotherapy (CRT-standard of care) 35 subjects T-cell induction has strong potential to enhance CRT anti-cancer efficacyMitigated riskPotential for rapid market penetration and market leadership Planned to be initiated Q4 2020

19 Unique triple combination including PDS0101 shows promising anti-tumor immune responses CD4 T-cells – GreenCD8 T-cells – RedDAPI - Blue PDS0101 promotes enhanced T-cell clonality Immunohistochemistry for CD4+ and CD8+ T cells in HPV-Positive tumors Reference: Smalley Rumfield C, Pellom ST, Morillon II YM, et alImmunomodulation to enhance the efficacy of an HPV therapeutic vaccine. Journal for ImmunoTherapy of Cancer 2020; 8:e000612. doi: 10.1136/jitc-2020-000612

20 PDS Biotechnology-sponsored Phase 2 study with KEYTRUDA® supplied by MerckKeytruda®: first immunotherapy approved as SOC for first line treatment of recurrent HNCPDS0101 monotherapy demonstrated high levels of circulating CD8+ killer T-cells and therapeutic benefitUnique immuno-oncology combination addressing first-line treatment of cancerStudy design: Phase 2 open-label studyPrimary endpoints: Efficacy, safety and tolerabilityInclusion criteria: Recurrent/metastatic head and neck cancer and HPV16 infectionPDS0101 dosed every 3 weeks for 4 doses (1st 4 cycles) with booster dose at cycle 12Keytruda dosed every 3 weeks (1st 4 in combo w/ PDS0101) until disease progression, intolerance or 2 yrsClinical Trial Identifier: NCT04260126 Planned Phase 2 study of PDS0101 in combination with KEYTRUDA® in first-line treatment of recurrent/metastatic head and neck cancer (HNC) Followed by open label SOC with KEYTRUDA® until disease progression or intolerance KEYTRUDA® alone Combination of PDS0101 and KEYTRUDA® 200 mg IV KEYTRUDA® every 21 days in combinationwith 3 mg SC PDS0101 at cycles 1, 2, 3, 4 and 12 Expected initiation: Q4 2020 based on current COVID-19-related restrictions on health system operations

Infectious Disease

22 The addition of Versamune® to Fluzone®, a seasonal influenza vaccine, resulted in a 40-fold increase in protective HAI titers – achieving superior levels of HAI titers with 5-fold lower doses of Fluzone® PDS0202: Versamune® dramatically enhances neutralizing antibody levels against various influenza strains and enables significant dose sparing

Preclinical testing of Versamune®-based COVID-19 vaccine candidates ongoing with a clear target profile 23 Ideal for rapid commercial scale up 4 No safety signals 3 Demonstrate high levels of both SARS-CoV-2-specific T-cell and antibody response after a single dose 2 Induction of highly-potent, SARS-CoV-2-specific killer T-cells 1

24 PDS0203: Versamune®-based COVID-19 vaccine induces rapid and potent antibody responses to SARS-CoV-2 in two weeks *Mice were immunized with two doses (day 0 and day 7) of vaccine, data collected 14- and 30-days post vaccination Initial preclinical data suggest Versamune® induces antibodies at a level equivalent to those observed in hospitalized COVID-19 patients within 2 weeks of vaccination

25 PDS0203: Versamune®-based COVID vaccine uniquely induces strong T-cell responses against SARS-CoV-2 in two weeks Mice were immunized with two doses (day 0 and day 7) of vaccine, data collected 14 days post vaccination. T-cells were measured by ELISPOT and CD8+ killer T-cells were measured by flow cytometry*Data for CD4+ T-cell response on file Preclinical data suggest Versamune® induces T-cells – including polyfunctional CD4+ (helper) & CD8+ (killer) T-cells - against SARS-CoV-2 when combined with either the Spike S1 protein or the full S-proteinStrong T-cell responses confirmed at 60 days: Long-lasting (memory T-cells)

Intellectual Property and Financials

27 Multiple layers of technology and product protection for Versamune®-related products through mid-2030s Versamune® and associated patents are owned and licensed by PDS BiotechPatents cover methods and compositions stimulating/promoting an immune response with Versamune® technology in various forms and mechanisms through 2034Use of specific cationic lipids to induce an immune responseCompositions and use of any cationic lipid to activate MAP kinaseCompositions and use of R-DOTAP to induce immune responseMicellar antigen + cationic lipids compositions (US still ongoing) Compositions of R-DOTAP with GM-CSF to reduce immune suppressive myeloid derived suppressor cells in the tumorFive issued international patent families (including Europe and Japan)

Strong financial position to support near-term milestones 28 Nasdaq PDSB Shares Outstanding* 22.3M Cash* $34.0M Share Price* $2.16 Market Cap* $48.2M Debt* --- PDS0101 (HPV): Initiation of NCI-led Phase 2 combination study in advanced HPV-associated cancersPDS0203 (SARS-CoV-2): Complete preclinical formulation development and feasibility testingPDS0101 (HPV): Initiation of MD Anderson-led Phase 2 combination study in advanced cervical-cancerPDS0101 (HPV): Initiation of VERSATILE-002 Phase 2 study of first line treatment of recurrent/ metastatic head and neck cancer in combination with KEYTRUDA®PDS0202 (influenza): Generate initial feasibility data on universal flu vaccinePDS0204 (SARS-CoV-2): Complete preclinical formulation development and feasibility testing Timing of 2020 milestones will be impacted by the COVID-19 pandemic * September 11, 2020

PDS Biotech poised to transform vaccines and cancer treatment by fulfilling the promise of immunotherapy 29 Clinical studies in areas of high unmet medical need supported by leaders in the field 4 Diversified pipeline focused on oncology and infectious disease 3 Demonstrated potential for strong clinical efficacy and durability of response with minimal toxicity 2 Powerful immunotherapy platform that activates therapeutic and preventive immunological pathways 1

Delaware	001-37568	26-4231384

(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Common Stock, par value $0.00033 per share	PDSB	The Nasdaq Capital Market

Exhibit Number		Description

99.1		Corporate Presentation dated September 2020.

	PDS BIOTECHNOLOGY CORPORATION

Date: September 15, 2020	By:	/s/ Frank Bedu-Addo, Ph.D.
	Name: Frank Bedu-Addo, Ph.D.
	Title: President and Chief Executive Officer